All In Biotech

Investigational drug · Phase 2

Antithymocyte globulin

Also called: ATG

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Transplant Rejection, Renal Transplantation.

Phase 2

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

563

Any phase or sponsor naming "Antithymocyte globulin"

First trial start

2022

Jun 9, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Antithymocyte globulin", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Transplant Rejection
  • Renal Transplantation

Approved drugs for the same conditions: Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Antithymocyte globulin" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 14,328 on PubMed

Also in development for Transplant Rejection

  • SAR445088Riliprubart, BIVV020Phase 35 trials

    Sanofi · Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic, Transplant Rejection

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.